Delcath Systems, Inc. (DCTH)
DCTH Stock Price Chart
Explore Delcath Systems, Inc. interactive price chart. Choose custom timeframes to analyze DCTH price movements and trends.
DCTH Company Profile
Discover essential business fundamentals and corporate details for Delcath Systems, Inc. (DCTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
3 May 2018
Employees
96.00
Website
https://www.delcath.comCEO
Gerard J. Michel MBA, MS
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Financial Timeline
Browse a chronological timeline of Delcath Systems, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 4 Mar 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.08.
Earnings released on 6 Aug 2025
EPS came in at $0.07 surpassing the estimated $0.03 by +169.23%, while revenue for the quarter reached $24.16M , beating expectations by +4.92%.
Earnings released on 8 May 2025
EPS came in at $0.03 falling short of the estimated $0.10 by -70.00%, while revenue for the quarter reached $19.78M , beating expectations by +6.11%.
Earnings released on 6 Mar 2025
EPS came in at $0.05 surpassing the estimated -$0.10 by +150.00%, while revenue for the quarter reached $15.10M , missing expectations by -9.43%.
Earnings released on 8 Nov 2024
EPS came in at -$0.03 surpassing the estimated -$0.13 by +76.92%, while revenue for the quarter reached $9.56M , missing expectations by -23.03%.
Earnings released on 5 Aug 2024
EPS came in at -$0.48 falling short of the estimated -$0.34 by -41.18%, while revenue for the quarter reached $7.77M , missing expectations by -19.02%.
Earnings released on 14 May 2024
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $3.14M , beating expectations by +43.33%.
Earnings released on 26 Mar 2024
EPS came in at -$0.48 surpassing the estimated -$0.67 by +28.36%, while revenue for the quarter reached $539.00K , missing expectations by -0.19%.
Earnings released on 13 Nov 2023
EPS came in at -$0.61 falling short of the estimated -$0.51 by -19.61%, while revenue for the quarter reached $434.00K , missing expectations by -19.63%.
Earnings released on 9 Aug 2023
EPS came in at -$0.58 surpassing the estimated -$0.67 by +13.43%, while revenue for the quarter reached $495.00K , missing expectations by -33.11%.
Earnings released on 22 May 2023
EPS came in at -$0.77 falling short of the estimated -$0.57 by -35.09%, while revenue for the quarter reached $597.00K , missing expectations by -22.47%.
Earnings released on 27 Mar 2023
EPS came in at -$0.86 falling short of the estimated -$0.68 by -26.47%, while revenue for the quarter reached $639.00K , missing expectations by -21.11%.
Earnings released on 8 Nov 2022
EPS came in at -$0.92 surpassing the estimated -$1.05 by +12.38%, while revenue for the quarter reached $906.00K , beating expectations by +13.08%.
Earnings released on 8 Aug 2022
EPS came in at -$1.18 falling short of the estimated -$0.88 by -34.09%, while revenue for the quarter reached $797.00K , beating expectations by +92.35%.
Earnings released on 10 May 2022
EPS came in at -$1.00 falling short of the estimated -$0.84 by -19.05%, while revenue for the quarter reached $378.00K , missing expectations by -43.84%.
Earnings released on 25 Mar 2022
EPS came in at -$0.69 surpassing the estimated -$0.93 by +25.81%, while revenue for the quarter reached $2.11M , beating expectations by +306.95%.
Earnings released on 9 Nov 2021
EPS came in at -$0.94 falling short of the estimated -$0.91 by -3.30%, while revenue for the quarter reached $522.00K , beating expectations by +6.53%.
Earnings released on 10 Aug 2021
EPS came in at -$0.96 surpassing the estimated -$0.98 by +2.04%, while revenue for the quarter reached $536.00K , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$1.04 falling short of the estimated -$0.89 by -16.85%, while revenue for the quarter reached $388.00K , missing expectations by -22.40%.
Earnings released on 31 Mar 2021
EPS came in at -$0.61 surpassing the estimated -$0.82 by +25.61%, while revenue for the quarter reached $507.00K .
Earnings released on 11 Nov 2020
EPS came in at -$1.16 falling short of the estimated -$1.15 by -0.87%, while revenue for the quarter reached $466.00K , missing expectations by -22.38%.
DCTH Stock Performance
Access detailed DCTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.